Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
- Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
- JPMA Issues Statement Calling for IP Protection, Expresses Concerns over Issuance of Compulsory Licenses
March 7, 2013
- Generic Market Share at 26.1% on Volume Basis in 3rd Quarter FY2012: JGA
March 6, 2013
- Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
- Yakukeiren’s Direct Joint Purchasing System for Generic Drugs to Go into Full Operation in FY2013
February 27, 2013
- TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
- JPMA’s Nakatani Says Transparency Guidelines Will Go into Force in April as Planned
February 25, 2013
- JPMA’s New Code of Practice to Take Effect in April; Transparency in Relations with Wholesalers to Be One Focus
February 22, 2013
- Osaka-Based NPO to Take on Outsourcing of GMP Compliance Audit on Drug Substance Makers
February 21, 2013
- Pharmaceutical Trade Deficit “Not Directly Related to Global Competitiveness” of Domestic Industry: Mr Nagasawa of OPIR
February 20, 2013
- JMA to Host WMA Expert Conference on Revision of Helsinki Declaration in Tokyo on Feb. 28
February 20, 2013
- Biotech Association Asks MHLW to Include Drugs for Intractable Diseases and Orphan Drugs in Early Approval System
February 18, 2013
- JMA President Yokokura Opposes TPP Agreement, Expressing Concerns over Intervention in NHI Pricing
February 15, 2013
- PPTA President Airs Concern over Japanese Govt Intervention in Price Setting of Blood Products
February 13, 2013
- RAD-AR Council to Set Guidelines for Information Provisioning on Ethical Drugs
February 12, 2013
- JMA Exec. Mikami Wants a Hold on Info Disclosures Based on Transparency Guidelines
February 8, 2013
- Permanent Introduction of Premium for New Drug Development One of PhRMA’s “Priorities in 2013”: Japan Chair
February 5, 2013
- JMA Submits Petition Calling on MHLW to include 7 Vaccines in Public Vaccination Program
February 1, 2013
- Wholesale Industry FTC Prohibits Drink Donations at Academic Confabs, Keeps Pace with Drug Makers
January 31, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…